Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study

Background & Aims: Patients with vascular liver diseases (VLD) are at higher risk of both severe courses of COVID-19 disease and thromboembolic events. The impact of SARS-CoV-2 vaccination in patients with VLD has not been described and represents the aim of our study. Methods: International...

Full description

Bibliographic Details

Published in:	JHEP Reports
Main Authors:	Valeria Perez-Campuzano, Pierre-Emmanuel Rautou, Thomas Marjot, Michael Praktiknjo, Edilmar Alvarado-Tapias, Laura Turco, Luis Ibáñez-Samaniego, Carlos González-Alayón, Ángela Puente, Elba Llop, Macarena Simón-Talero, Carmen Álvarez-Navascués, Thomas Reiberger, Xavier Verhelst, Luis Tellez, Johanna Birte Bergmann, Lara Orts, Giuseppe Grassi, Anna Baiges, Payance Audrey, Jonel Trebicka, Candid Villanueva, Maria Cristina Morelli, Sam Murray, Georgina Meacham, Marc Luetgehetmann, Julian Schulze zur Wiesch, Juan-Carlos García-Pagán, Eleanor Barnes, Aurélie Plessier, Virginia Hernández-Gea
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Subjects:	Vascular liver disease COVID-19 vaccine portal thrombosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589555924001952